Financing ·
Silexion Therapeutics Corp consummated a public offering on August 13, 2026, raising approximately $2.5 million in…
SLXNSilexion Therapeutics Corp
Silexion Therapeutics Corp consummated a public offering on August 13, 2026, raising approximately $2.5 million in gross proceeds by selling ordinary shares and pre-funded warrants at $0.65 per unit. The company also converted $750,001 of principal from its Sponsor Note into 1,153,848 ordinary shares at the offering price, reducing the note balance to $206,462. Net proceeds were estimated at $2.1 million after deducting placement agent fees and expenses. The company intends to use the capital to advance its SIL204 clinical trial for locally advanced pancreatic cancer and for general corporate purposes. Silexion Therapeutics is a clinical-stage biotechnology company developing RNA interference therapies for KRAS-driven cancers.